FDA warns about unapproved medications from a Canadian supplier


FDA warns about unapproved medications from a Canadian supplier

The U. S. Food & Drug Administration (FDA) has warned more than 350 medical practices that they might have received unapproved, counterfeit or unsafe medications from a Canadian supplier.

The federal food and drugs regulator said that the medications, including unapproved variants of Botox, could harm patients as they could be counterfeit or contaminated.

The foreign supplier who allegedly supplied the unapproved medications to the U. S. medical practices is operated by Canada Drugs, which is also called Quality Specialty Products (QSP), QP Medical or Bridgewater Medical.

In the letter written to the medical practices, the federal agency said, "FDA is very concerned that products distributed by these suppliers may cause harm to patients, because they may be unsafe or ineffective."

The FDA also warned doctors about purchasing drugs from any source other than pharmacies licensed by the U. S. authorities.

Dr. Peter B. Fodor, a plastic surgeon and an expert on Botox, also warned that using a non-FDA approved Botox could be very dangerous.

This is the fifth warning issued by the FDA this year about a foreign supplier supplying unapproved medications.


Latest News

Sources Say ABInBev will Possibly Raise SABMiller Bid to Around 43 to 44 Pounds
William Lewis
Weaker Dollar and Lower U.S Rig Count Help Oil Edge Up
Gold Gains as Investors do not See any Chance of US Rate Hike Immediately
Contract Fees is the Key Reason for Tegna and Dish Spat
A Rise in the Medicare Premiums Could Mean Huge Increase for some and Opportunit
Organization for Economic Co-operation and Development
New Twitter CEO Expected to Cut Costs and Bring Changes
Deutsche Bank Q3 Loss may be a Record One in a Decade
Volkswagen Scandal Worries the City of Wolfsburg
Strong Component Sale and Weak Won help Samsung’s Third Quarter Profits
Is the U.S. Shale Oil Boom Heading Towards the Beginning of Its End?